Highlights argenx SE

Equities

ARGX

NL0010832176

Market Closed - Euronext Bruxelles Other stock markets 11:35:22 2024-04-30 am EDT			5-day change	1st Jan Change
350.8 ^EUR	+0.66%		+0.46%	+2.13%

Apr. 17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 16	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	Apr. 16	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	Mar. 27	CI
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	Mar. 26	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	Mar. 21	DJ
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo...	Feb. 29
Argenx Q4 Loss Widens, Revenue Increases -- Shares Down Pre-Bell	Feb. 29	MT
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo	Feb. 20	MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	Feb. 20	CI
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients	Jan. 18	MT
Japanese Health Regulator Approves Argenx's Generalized Myasthenia Gravis Treatment	Jan. 18	MT
Argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis	Jan. 18	CI
Exchange-Traded Funds, US Equities Fall Pre-Bell Wednesday as Investors Await US Consumer Confidence, Home Sales Reports	Dec. 20	MT
Argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus	Dec. 20	CI
Zai Lab Shares Climb as Vyvgart, Nuzyra, Zejula Added to 2023 China Reimbursement Drug List	Dec. 13	MT
Zai Lab Says China Added Vyvgart, Nuzyra, Zejula to 2023 Reimbursement Drug List	Dec. 13	MT
Fed Officials Comments Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Nov. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights argenx SE

Equities

ARGX

NL0010832176

Highlights

Filters